secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107304
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.
- R&D expenses of $22.5M (down 20% YoY); G&A expenses of $7.0M (down from $8.6M).
- MGX-001 hemophilia A program: IND/CTA submission planned in 2026; durable FVIII activity shown through 19 months in NHP study.
- Appointed Laurence Reid, Ph.D., to Board of Directors in August 2025; established an R&D Committee.
- Presented three abstracts at ASGCT on compact nucleases and CAST systems for targeted gene integration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/0000950170-25-107304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/mgx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer